{"id":"311e9cc4-68db-4d74-b74c-33fd30682fc4","name":"Edwards Lifesciences","slug":"edwards-lifesciences","description":"Edwards Lifesciences is an American medical technology company headquartered in [Irvine, California](https://en.wikipedia.org/wiki/Irvine,_California), specializing in tissue heart valves and transcatheter technologies for structural heart disease. Founded by Miles Lowell Edwards in 1958, the company invented the first successful artificial heart valve (the Starr-Edwards valve) and pioneered transcatheter aortic valve replacement (TAVR) with its [SAPIEN 3](https://www.edwards.com) platform. The company is listed on the NYSE (EW) and is an S&P 500 component.","status":"active","founded":1958,"hq":"Irvine, California, USA","hqLat":33.6856969,"hqLng":-117.825981,"hqGeocodedAt":"2026-08-05T14:27:55.168Z","hqAddress":null,"hqPrecision":null,"website":"edwards.com","fundingTotal":null,"type":"both","roles":["robot_maker","robot_operator"],"reviewStatus":"reviewed","heatIndex":58,"lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://www.edwards.com/","title":"Edwards","date_accessed":"2026-06-07"}],"keyFacts":[{"label":"CEO","value":"Bernard J. Zovighian"},{"label":"Previous CEO","value":"Michael Mussallem (2000-2023, founder-era leader who took company public)"},{"label":"Founder","value":"Miles Lowell Edwards (electrical engineer, invented first artificial heart valve)"},{"label":"NYSE Ticker","value":"EW"},{"label":"S&P 500 Component","value":"Yes"},{"label":"Key Product","value":"Cordella Pulmonary Artery Sensor (FDA-approved June 2024 for heart failure management)"},{"label":"Manufacturing","value":"Irvine CA, Draper UT, Costa Rica, Singapore, Limerick Ireland, Moncada Spain (under construction)"},{"label":"Parent Company History","value":"Acquired by Baxter International 1985, spun off in 2000 IPO"},{"label":"Revenue 2025","value":"US.07 billion"},{"label":"Employees","value":"16,000 (2025)"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":"EW","stockExchange":"NYSE","secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":16000,"employeeCountBasis":"reported","employeeCountAsOf":"2025-12-31T12:00:00.000Z","marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-06-08T04:27:19.214Z","updatedAt":"2026-08-21T22:29:08.868Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/edwards-lifesciences","url":"https://registry.deploy.report/companies/edwards-lifesciences","name":"Edwards Lifesciences","description":"Edwards Lifesciences is an American medical technology company headquartered in [Irvine, California](https://en.wikipedia.org/wiki/Irvine,_California), specializing in tissue heart valves and transcatheter technologies for structural heart disease. Founded by Miles Lowell Edwards in 1958, the company invented the first successful artificial heart valve (the Starr-Edwards valve) and pioneered transcatheter aortic valve replacement (TAVR) with its [SAPIEN 3](https://www.edwards.com) platform. The company is listed on the NYSE (EW) and is an S&P 500 component.","identifier":"311e9cc4-68db-4d74-b74c-33fd30682fc4","foundingDate":"1958","address":"Irvine, California, USA","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}